Acute Lymphoblastic Leukemia Study
COG#AALL0331 Standard Risk B-Precursor Acute Lymphoblastic Leukemia
Protocol ID
Protocol Description
The overall goal of this study is to see if we can rid patients of acute lymphoblastic leukemia (ALL) for as long as possible with acceptable side effects of therapy.
Part I of this study will collect information about the leukemia and about the effects of the first phase of treatment, called Induction, which lasts 5-7 weeks. Patients in this study will have already signed a consent form for the ALL Classification Study AALL03B1.Their doctors will know the subtype of the ALL by the end of Induction.
During and at the end of Induction, tests will be done on the bone marrow samples to find out how well the treatment is working. This helps the study doctors know how strong the rest of your treatment needs to be to keep the leukemia in remission.
Patients will be offered the chance to take part in Part II of this study once the ALL subtype is known.
Eligibility Criteria
Children and adolescents with acute lymphoblastic leukemia (ALL)
Primary Investigator(s)
- Arlene Redner, MD